LTRN — Lantern Pharma Share News
0.000.00%
Last trade - 00:00Lantern Pharma Inc expected to post a loss of 51 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-PSQ Holdings, Core Scientific, Keros
U.S. STOCKS ON THE MOVE-BlackRock, Terns Pharma, PSQ Holdings
U.S. STOCKS ON THE MOVE-Citi Trends, PG&E, BlackRock
Lantern Pharma rises on FDA 'fast track' tag for breast cancer drug
Brief: Lantern Pharma & Starlight Therapeutics Present LP-184
Brief: Lantern Pharma Announces First Patient Dosed In Japan
Lantern Pharma Inc reports results for the quarter ended in September 30 - Earnings Summary
Lantern Pharma Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Starlight Therapeutics Announces Inaugural Members Of Scientific Advisory Board
Brief: Lantern Pharma’S Investigational Drug-Candidate, Lp-184, Receives Fast-Track Designation In Glioblastoma From The FDA
U.S. STOCKS ON THE MOVE-US energy sector, gold miners, AeroVironment
U.S. STOCKS ON THE MOVE-Meta, US energy sector, gold miners
Lantern Pharma up on FDA's rare pediatric disease tag for cancer therapy
Brief: Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted To Lp-184 In Multiple Ultra Rare Children’S Cancers
Lantern Pharma Inc reports results for the quarter ended in June - Earnings Summary
Lantern Pharma Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Lantern Pharma Receives Certificate Of Patent From Japanese Patent Office For Composition Of Matter Covering Drug Candidate LP-284
Brief: Lantern Pharma Inc Files For Mixed Shelf Of Upto $150 Mln